The invention relates to the treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting αv-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants thereof.本發明係關於藉由抗體來治療纖維化及/或纖維化疾病。首先，本發明係關於投與抗-αv整合素(受體)抗體至罹患纖維化及/或纖維化疾病(包括但不限於全身性硬化症(SSc))之患者。更具體言之，本發明係關於藉由該抗體來治療皮膚、肺、心臟、肝及/或腎之纖維化疾病。甚至更具體言之，本發明係關於藉由抗-αv整合素抗體DI17E6及其結構突變體來投與靶向αv整合素之重組型脫免疫單株抗體至罹患全身性硬化症(包括但不限於皮膚、肺、心臟及/或腎之全身性硬化症)之患者。
